Patient no. | ISS stage | Sex | Age (years) | Introduction therapy/cycles | Response | Therapy after PD/cycles | Survival status | PFS (months) | OS (months) |
---|---|---|---|---|---|---|---|---|---|
1 | III | Male | 51 | CTD/5 | CR | RAD/6 | Alive | 6.0 | 17.6 |
2 | III | Female | 53 | CTD/7 | PR | RD/8 | Alive | 8.0 | 19.5 |
3 | III | Male | 64 | VCD/1 | PD | NA | Dead | 0.7 | 0.9 |
4 | III | Male | 48 | VTD/8 | PR | RCD | Dead | 26.2 | 44.3 |
5 | III | Female | 59 | VTD/2 | SD | NA | Dead | 5.1 | 5.7 |
6 | III | Male | 44 | VCD/9 | CR | TAD/6 + RAD/6 | Alive | 42.3 | 47.0 |
7 | III | Female | 49 | VTD/9 | CR | RAD/10 | Dead | 28.0 | 42.6 |
8 | III | Male | 52 | VCD/9 | VGPR | RD/6 | Dead | 8.5 | 13.0 |
9 | III | Male | 45 | VCD/2 | CR | CTD/8 | Alive | 2.4 | 9.2 |
10 | III | Male | 59 | VD/4 | PR | VCTD/5 | Dead | 16.7 | 16.7 |
11 | III | Male | 51 | CTD/5 | PR | RAD/3 | Dead | 10.0 | 6.6 |
12 | III | Female | 56 | VCD/4 + ASCT | VGPR | CTD/4 | Dead | 18.7 | 22.9 |
13 | III | Female | 66 | VD/4 | VGPR | RD/6 | Dead | 48.0 | 66.0 |